STAT Plus: Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management
Top of the morning to you, and a fine one, it is. Despite another round of overcast skies enveloping the Pharmalot campus, we are maintaining a stiff upper lip and a sunny outlook. After all, as the Morning Mayor taught us: Every new day should be unwrapped like a precious gift. While you tug on the ribbon, we will fire up the coffee kettle for another cup of stimulation. Meanwhile, here are a few items of interest to stimulate your own neurons. Hope your day is successful and, as always, please do keep in touch.
Another, less likely victim of the outbreak: India’s pharmaceutical industry, The South China Morning Post explains. India imports nearly 70% of its raw materials and active ingredients from China, about $4.5 billion each year. Since 2015, pharmaceutical ingredients have been among India’s top 10 imports from China and a sizable chunk of these were used in the $19.1 billion worth of pharmaceutical products that the latter exported last financial year, according to official figures.
Continue to STAT Plus to read the full story…
